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In Brief
Naguib et al. use a mass-spectroscopy-
based method to identify and
characterize phosphatidylinositol acyl
chains, the lipid scaffold that forms the
basis of PI3K/AKT signal transduction.
Using genetic models of cancer, they
identify p53 mutation as a modulator of
these molecules, finding that these lipids
are changed in response to genetic
alterations of this tumor suppressor.
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Phosphatidylinositol phosphate (PIP) second mes-
sengers relay extracellular growth cues through the
phosphorylation status of the inositol sugar, a signal
transduction system that is deregulated in cancer.
In stark contrast to PIP inositol head-group phos-
phorylation, changes in phosphatidylinositol (PI)
lipid acyl chains in cancer have remained ill-defined.
Here, we apply a mass-spectrometry-based method
capable of unbiased high-throughput identification
and quantification of cellular PI acyl chain composi-
tion. Using this approach, we find that PI lipid chains
represent a cell-specific fingerprint and are unper-
turbed by serum-mediated signaling in contrast to
the inositol head group. We find that mutation of
Trp53 results in PIs containing reduced-length fatty
acid moieties. Our results suggest that the anchoring
tails of lipid second messengers form an additional
layer of PIP signaling in cancer that operates inde-
pendently of PTEN/PI3-kinase activity but is instead
linked to p53.
INTRODUCTION
The phosphatidylinositol phosphates (PIPs) emerged as central
to cellular signaling subsequent to the revelation that the pattern
of their phosphorylation status formed a code for intracellular
signal transduction (Whitman et al., 1988). They serve pivotal
roles in normal cellular processes and a broad spectrum of pa-
thologies (Aoyagi and Matsui, 2011; Courtney et al., 2010; Liu
and Bankaitis, 2010). The unphosphorylated phosphatidyli-
nositol (PI) forms the scaffold upon which multiple kinase and
phosphatase-dependent events occur, which generate the PIP
second messengers of growth control. They signal through mul-
tiple axes, including the phosphatidylinositol 3-kinase (PI3K)/
AKT pathway, which is aberrant in a majority of cancers. PIs
are glycerophospholipids, composed of a glycerol central moi-
ety with two fatty acid esters, a phosphate ester in the third
position, and an inositol ring (‘‘head group’’) bound to the phos-
phate group (Figure S1A). Variable and combined phosphoryla-
tion of PIs on the 30, 40, and 50 positions of inositol generates
seven distinct variants. Extracellular ligand-stimulated PI3K acti-8 Cell Reports 10, 8–19, January 6, 2015 ª2015 The Authorsvation generates PI(3,4,5)P3, which promotes cell survival and
growth (Cantley, 2002). The tumor suppressor PTEN, frequently
inactive in cancer (Hollander et al., 2011), antagonizes PI3K func-
tion by its conversion of PI(3,4,5)P3 to PI(4,5)P2. In addition to
malignant scenarios, PIPs mediate growth cues in develop-
mental and other biological processes (Clague et al., 2009;
Comer and Parent, 2007; Moss, 2012). Thus, the head-group
status of these lipid second messengers has taken center stage
in investigations of PIP biology, while the lipid tails have been
assumed to play a limited role in signaling.
Here, we report the application of a mass spectrometry-based
high-throughput method for global analysis of PIs. With this
application, we dissected the dynamic nature of the PI signaling
scaffold upon which second messengers are formed, demon-
strating that in response to mutation of p53, reduced-length fatty
acid moieties are present in cellular PIs.
RESULTS
Global Assessment of Cellular PI-Lipid Content
To analyze global PI-lipid content, we adapted electrospray-ioni-
zation multiple reaction monitoring (MRM) methodologies for the
assessment of the total compliment of PI variants present in cells
and tissue. Identification of the most abundant PI species pre-
sent in each cell line was possible via interrogation of ions with
700–1,200 m/z with signals corresponding to anticipated PI
masses (Figures S1B andS1C) clearly identifiable. For prominent
PI species, both molecules containing minor differences in iso-
topic composition and molecules varying by differences in satu-
ration status could be discerned (Figure S2F). Identification of
the mono (phosphatidylinositol phosphate- PIP) and bis (phos-
phatidylinositol bisphosphate- PIP2) forms of the most abundant
PI species was achieved. We termed these phosphatidylinositol
families ‘‘triplets’’ (Figure S1C, left panel). Each additional phos-
phate moiety contributes an increased 80 m/z, such that the PI
for any particular species may be given as ‘‘N’’ m/z, the PIP as
N + 80 m/z, and the PIP2 N + 160 m/z. Of note, in our analysis,
phosphatidylinositol triphosphate (PIP3) was not apparent at
levels above those of background. However, subsequent frag-
mentation of ions with a predicted m/z (i.e., N + 240 m/z) corre-
sponding to anticipated PIP3 masses generated PIP3-specific
ions (Milne et al., 2005; Wenk et al., 2003), demonstrating the
presence of these molecules, although at abundances with
signal-to-noise ratios significantly below 3:1 (data not shown).
In order to positively identify lipid species, fragmentation of
parent ions corresponding to anticipated PI m/z was performed
(Figure S1C, right panel). These detailed fragmentation spectra
allowed unambiguous identification of parent ions, with identifi-
cation of both the fatty acid and head-group components of
lipids, consistent with previous descriptions of PI fragmentation
spectra (Hsu and Turk, 2000; Ivanova et al., 2009). Fragmen-
tation patterns were compared to known phospholipid stan-
dards to confirm their phosphoinositide-derived nature (data
not shown).
To enable high-throughput identification and quantification of
individual PIs, we developed a method employing automated
sample injection, fragmentation, and ion measurement. MRM,
using anticipated PI fragment ions as parent masses and calcu-
lated daughter ions, corresponding to inositol head-group and
acyl chain configurations observed in preliminary PI fragmenta-
tion experiments, permitted broad assessment and quantifica-
tion of PI species (Figure S1E). The abundances of 20 anticipated
PI variants were measured in tandem to generate robust quanti-
fication data for each individual molecule. Initial experiments
interrogated ions in the 300–1,300 m/z range. In no experiments
did we observe PI species <800 m/z and >920 m/z, as deter-
mined by ion fragmentation of parent masses. Therefore, in sub-
sequent analyses, we restricted our analysis to PI molecules in
this mass range (Figure S1B). It should be noted, however, that
although in none of the initial tests of cultured cell lines were
PIs containing acyl chains of >20 carbons observed, some tissue
types, such as rat liver (Patton et al., 1982), have been shown to
contain low amounts of PIs with fatty acid components of more
than 20 carbons. Resultantly, for detailed assessment of previ-
ously unexamined tissues using this method, pilot scans interro-
gating masses greater than 900 m/z could be performed.
Total ion chromatograms (Figure S1D) highlight that the
extraction protocol employed does not generate PI-pure lipid
mixtures. However, assessment of PI-specific daughter ions,
and not putative parent ion masses, enables specific measure-
ment of PI abundance, providing the molecular specificity of
this method. All potential acyl chain saturation states (including
hypothetical variants) for each predicted PI are assessed with
no prior understanding of molecular configuration required. For
example, PI 889 m/z corresponds to the molecular configuration
38:2 (a total acyl chain composition harboring 38-carbon atoms
and two double bonds). From the empirical formula, it is not
possible to determine acyl chain length/saturation status. To
overcome this, all potential fatty acid configurations that the
molecule may comprise were measured simultaneously: 18:0,
18:1, 18:2, 20:0, 20:1, and 20:2. Of note, in our analysis, we failed
to observe acyl chains with odd-numbered carbon atoms. These
configurations are presumably not utilized or generated by cells
or, if so, in abundances below the level of detection. In summary,
this adapted method enabled unbiased, PI-specific lipid quanti-
fication in an automated, high-throughput manner and can be
performed in the absence of any prior molecular knowledge of
the target lipid(s) of interest. Fragmentation of lipid standards
comprising 16:0/18:1 and 18:0/20:4 fatty acids revealed compa-
rable fragmentation and ion generation, suggesting that PI frag-
mentation across molecular species did not vary as a function of
fatty acid length (Figure S1F), thereby allowing direct compari-
son of quantified ions between PI lipid species.Electrospray ionization techniques have been employed previ-
ously with great success in identification of PI, PIP, PIP2, and
PIP3 (Milne et al., 2005;Wenk et al., 2003). However, previous re-
ports have not attempted to quantify these molecules. A more
advanced lipid extraction/analysis procedure with incorporation
of phosphate methylation steps and high-performance liquid
chromatography has also been developed for the assessment
of phosphatidylinositol phosphates, including PIP3 (Clark et al.,
2011). However, to date, the ability to globally quantify phospha-
tidylinositol phosphates has remained elusive. In our hands, the
quantification of PIP and PIP2 content was achieved, albeit with
large observed deviations between samples (data not shown). At
present, it is unclear whether these deviations are due to biolog-
ical phenomena or lower abundances of themolecules being as-
sessed. Furthermore, analysis of lipid standards demonstrated
that ionization of equivalent molar amounts of PI, PIP, PIP2,
and PIP3 did not generate equivalent ion abundances (data not
shown), further complicating the direct comparison of phospha-
tidylinositides of disparate phosphorylation status.
PI Lipid Tail Fingerprints
Assessment of Pl lipids was performed across multiple cells line
with high reproducibility achieved across biological replicates.
Analysis of cells of both human and mouse origin revealed that
disparate cancer cell lines possessed unique PI characteris-
tics—a PI-lipid fingerprint (Figure 1). In addition, it was apparent
that the cell lines tested did not harbor exclusive PI acyl chain
lengths but mostly also the closely related sibling molecules
differentiated by saturation state of the fatty acid moieties.
Quantification of the four most abundant PI-lipid species (Fig-
ure S2A) revealed that, strikingly, 40%–50% of the total PI
composition of cells is composed of just two PI-lipid masses.
Approximately 70% of the total PI content in cells contained
the four most abundant lipid masses in any single cell line. Hu-
man and murine cells demonstrated no remarkable differences
in this analysis.
Assessment of the saturation status of PI lipid chains demon-
strated that in the cell very few of these lipids are polyunsatu-
rated. These data also revealed that saturation of cellular PIs in
murine and human cells does not differ significantly. Of note,
however, NIH 3T3 and Capan-2 (a pancreatic cancer-derived
line) cells harbored fewer monounsaturated PI lipids and higher
levels of three or four double-bond-containing lipids than the
other lines assessed (Figure S2B).
Analysis of the carbon content, which reflects fatty acid chain
length, revealed that the majority of PIs possessed 34-, 36-, or
38-carbon atoms in their fatty acid components (Figure S2C).
NIH 3T3 and Capan-2 lines contained a higher proportion of
38-carbon PIs comparative to the other cells tested.
PI Acyl Chain Content Is Not Affected by Extracellular
Ligands but Is Dependent on Serum-Derived Essential
Fatty Acids
In order to assesswhether thePI-lipid fingerprint of each cultured
cell line was altered in response to extracellular ligands, cultured
cells were serum starved for 24 hr before PI lipid analysis. Unlike
in the case of PI head-group phosphorylation, removal of serum-
provided extracellular ligands had no effect on PI lipid chainCell Reports 10, 8–19, January 6, 2015 ª2015 The Authors 9
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composition (Figure 1B). Comparison of the abundances of the
20 quantified PI masses in normal culture and 24 hr serum-
starved conditions identified no change in PI-lipid abundances
at a statistically significant level (Figure S2D, HCT116 cells
shown). Testing of PI-lipid characteristics in response to 24 hr
serum withdrawal in multiple additional cell lines confirmed the
lack of response to extracellular ligands (data not shown).
We then sought to investigate PI-lipid composition when cells
are grown in the absence of fatty acids, another component pro-
vided by fetal bovine serum (FBS) in tissue culture contexts. To
this end, three cultured cell lines (HeLa, NIH 3T3, and PC3)
were grown in medium supplemented with delipidated FBS.
Subsequent to 3 days growth in delipidated medium, all cell
types exhibited a reduced proliferation compared to control ex-
periments supplemented with normal FBS (Figure S3A). In the
case of NIH 3T3 cells, lack of lipid supplementation led to an
overall reduction in cell number with most of the plated cells per-
ishing. PI acyl chain characteristics were then investigated. For
all lines, in both lipidated and delipidated scenarios, the 38:3 PI
species was in the vast majority composed of PIs containing
18:0 and 20:3 fatty acids, with a limited amount of 18:1/20:2 var-
iants detectable (data not shown). For the 38:4 species, all cells
harbored mostly 18:0/20:4 PIs, but with some 18:1/20:3 acyl
species present in both lipidated and delipidated contexts
(data not shown).
Some fatty acid molecules incorporated into PIs, such as lino-
leic acid (18:2), are not produced by the cell and in tissue culture
scenarios must be provided in serum. Linoleic acid, for instance,
is utilized as a precursor in the production of arachidonic acid
(20:4) (Steinberg et al., 1956). Although some variations in total
cellular PI-lipid content (Figure S3B) are observed after removing
lipids from culturemedium, the greatest effect appeared to be on
cell viability/proliferation. Our initial studies suggest that cells
lack a large degree of plasticity regarding their fatty acid compo-
sition in response to environmental changes, and when cells are
unable to acquire the optimal fatty acid configurations for lipid
production, their viability is compromised. In the absence of lino-
leic acid in culture medium, we assume that levels of this acid,
and arachidonic acid, were remnants from the original cell mate-
rial plated at the start of the experiment.
Testing the Conservation of PI-Lipid Fingerprints
In order to determine some of the underlying parameters respon-
sible for a cell’s PI-lipid fingerprint, we generated cultured
cell lines with known genetic lesions and well-characterized ori-
gins. Genetically engineered mice were generated harboring
pancreas-specific Kras and Trp53 mutations. These genetic le-Figure 1. PI Characteristics Are Unique to Disparate Cancer Cell Lines
(A) Representation of quantification of phosphoinositide abundances in the com
independent lipid preparations and measurements. Individual sample measurem
carbon content of both lipid fatty acids is displayed as ‘‘number of carbon atoms
highest abundance (right vertical axis).
(B) Assessment of PI the characteristics of the HCT116 cells in both normal (10%
(C) Assessment of two genetically engineered cell lines derived from mouse pan
Trp53 mutations) from independent mice with identical backgrounds.
(D) Assessment of two independent and distinct human pancreatic adenocarcinom
displayed (error bars, ±SD).sionswere sufficient to generate pancreatic neoplasia in thesean-
imals, and from these malignancies, culture lines were generated
from two animals with identical strain background and identical
tumor-initiating/driving genetic lesions (Figure 1C).
Using these two lines,wewere able to address thequestion: do
tumor cell lines, from the same genetically modified cancerous
organ, but different individuals, retain the same lipid fingerprint?
Quantification of thePI abundances in the two lines andstatistical
testing revealed that the PI lipid fingerprints were not statistically
significantly different (Figures 1C and S2E). Furthermore, com-
parison of the saturation status and acyl chain carbon content
of thePIs confirmedan unalteredPI content in thesedisparate tu-
mor-derivedcell culture lines. Thesedata suggested that cancers
from different individuals, but triggered by the same mutations,
share common PI acyl chain characteristics, thereby indicating
the potential use of PI fingerprints in diagnostic contexts.
Our analysis also includes the study of the HCT116 and KO22
culture lines (Figures 1B and S2G). HCT116 cells were originally
derived from a colorectal cancermetastasis. KO22 cells were en-
gineered fromHCT116 cells by knockout of the PTEN tumor sup-
pressor gene (Lee et al., 2004). These two cell lines also showed
the same PI-lipid profile. This result suggested that PTEN status,
responsible for regulation of PIP head-group phosphorylation,
had no effect on PI lipid tail features. In addition, the finding sug-
gested that two closely related but genetically distinct cancer cell
lines,whichwerecultured independently for adecadesincediver-
gence, retained similar lipid profiles. On the whole, these data
support the notion that the PI-lipid content of cells is fixed and
not significantly altered by extensive passaging in tissue culture.
Next, we tested two human pancreatic cancer-derived lines,
Capan-2 and MiaPaCa-2, both classified as pancreatic carci-
nomas (Kyriazis et al., 1986; Yunis et al., 1977), which showed
distinct PI fingerprints (Figure 1D). This observation suggests
that organ of origin does not dictate cellular PI characteristics
for cancer cells. It is plausible in the instance of these two
pancreatic carcinomas that independent genetic events, which
contributed to their malignant development, precipitated the
divergence of disparate lipid profiles. Conversely, the genetically
engineered cell lines, obtained from mouse pancreas adenocar-
cinomas (Figure 1C) of identical genetic lineage, presented indis-
tinguishable PI-lipid fingerprints.
Nonmalignant Cells Harbor Primarily 38-Carbon PIs
To disentangle factors that may cause cells to harbor PIs specific
acyl chain composition, we used primary mouse embryonic fi-
broblasts (MEFs; note that the protocols for mouse experiments
were in accordancewith institutional guidelines and approved byand Are Dictated by Genetics and Not Growth Factors
mon laboratory cell lines NIH 3T3 and HeLa. Graphs are derived from two
ents were derived from three measurements of the same sample. The sum
’’ (left vertical axis). Relative ion counts are normalized to the ion of observed
serum) and serum-starved (0.1%) conditions.
creas tumors. Cancers were initiated with identical genetic lesions (Kras and
a cell lines. For all graphs, meanmeasurements of two biological replicates are
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Figure 2. PI Fingerprint of Noncancerous Tissue and Cells
Assessment of PI characteristics from primary wild-type MEFs and mouse tissue obtained a resection. For MEFs, mean measurements of two biological rep-
licates are displayed (error bars, ±SD). For tissues, mean measurements of technical triplicates are displayed (error bars, ±SEM). Animals from which tissue was
taken were healthy, 7-week-old wild-type males. Blood was entire fluid containing both serum and cellular components.the Institutional Animal Care and Use Committee [IACUC]). Strik-
ingly, assessment of wild-type primary MEFs revealed that they
harbored a PI-lipid profile dominated by 38-carbon acyl chain
content (Figure 2), highly similar to that seen in NIH 3T3 cells
and in stark contrast to all cancer cell lines tested (Figures 1A,
right panel, 1B–1D, and S2G). Most primary tissues from mouse
displayed the same type of dominant 38-carbon lipid chain con-
tent in their PIs (Figure 2), suggesting that it represents a normal
state with the exception of brain and testicle (Figure S2F), which
also possessed a single, unique, additional PI-lipid m/z (835 and
809 m/z, respectively).
p53 Mutation Status Dictates Changes in PI-Lipid
Fingerprints
We then went on to analyze mouse-derived pancreatic cancer
cell lines, as shown in Figure 1C, but in a comparative context
of other genetic lesions and normal, noncancerous pancreas tis-
sue (Figure 3). Normal mouse pancreas demonstrated a PI-lipid
fingerprint similar to wild-type MEFs and NIH 3T3 cells: almost
exclusively 38-carbon acyl chain content. In contrast, the pancre-
atic cancer cells, generated frompancreas engineered to achieve
pancreas specific expression of KrasG12D and Trp53 R172H muta-12 Cell Reports 10, 8–19, January 6, 2015 ª2015 The Authorstion from the endogenous alleles demonstrated a significant shift
to lower PI carbon content. Analysis of pancreas-derived tumor
lines generated harboring solely the oncogenic KrasG12D muta-
tion, in the absence of Trp53 alteration, retained a PI-lipid profile
indistinguishable from normal pancreas tissue.
To confirm that shifts in PI lipid composition are not simply the
result of increased proliferation, we analyzed the PI fingerprint of
the primary Trp53D/DMEFcell line (Figure 3B; generated using the
Cre-loxP/viral system; Chen et al., 2005). As a result of this p53
loss-dependent immortalization, these cells have significantly
enhanced proliferation compared to wild-type MEFs (Chen
et al., 2005). Irrespective of their increasedgrowth rates, however,
Trp53 null MEFs did not share the PI-lipid fingerprint of
Trp53 +/R172H, Kras+/G12D cells; these data suggested that
changes in the population of cellular PI acyl chain moieties corre-
lates with p53 mutation, but not loss.
To further explore the relationship between p53 mutation and
PI characteristics, we sought to correlate human p53 mutation
status with cellular PI content. In all cell lines harboring TP53mu-
tation, we identified a corresponding high level of 36-carbon PIs.
Two cell lines absent of TP53mutation did not exhibit this shift in
PI-lipid composition: the prostate cancer metastasis-derived
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line PC3, and the pancreatic cancer-derived line Capan-2.
Sequencing of PC3 DNA demonstrated heterozygous loss of
one allele of TP53 and a frameshift mutation in the remaining
allele, rendering this line TP53 null (Figure 4B). Sequencing of
the mutation cluster region of TP53 (exons 5–8) of Capan-2
DNA revealed no TP53mutations (data not shown), in agreement
with previous reports describing the TP53 wild-type nature of
this line (Caldas et al., 1994; Loukopoulos et al., 2004). The lipid
fingerprint of this line lacked high levels of 34- and 36-carbon PIs
(Figure 1D, left panel). Resultantly, genetic analysis of cultured
cancer cells pointed to a link between TP53 mutation status
and increased 34- and 36-cabon PI-lipid content.
In order to assess if p53mutation alone could cause the transi-
tion of cellular Pl lipids from 38- to 36-/34-carbon acyl chain
length, we employed a lox-stop-lox Trp53R270H MEF system.
Cre recombinase causes recombination at the Trp53 locus to ex-
press the mutant Trp53 gene from the endogenous Trp53 pro-
moter (Tuveson and Hingorani, 2005). We harvested a panel of
littermate primary MEFs of the two genotypes Trp53+/+, which
served as wild-type control MEFs before and after Cre-mediated
recombination, and Trp53lslR273H/+. A total of 12 primary cells of
these two genotypes were cultured and independently infected
or not at passage 2. The PI content of the cells was then deter-
mined 6 days subsequent to infection and analyzed in blinded
experiments on 24 samples (12 littermate MEF samples with or
without viral addition).When lipiddata fromCre-recombinedcells
were plotted stratified by Trp53 status, variability in 36-carbon
acyl chain content (relative to 38-carbon content) became
apparent (Figure 5A). Unblinding revealed that the eight Trp53
mutant MEF lines had higher 36-carbon content lipids than their
Cre-infectedTrp53wild-type littermate controls.Whenassessing
the recombination effect on a line-by-line level (Figure 5B), we
found that mutant Trp53 expression induced an approximate
50% increase in 36-carbon content PI lipids on average, an in-
crease observed in every before/after Cre paired comparison.
Importantly, no significant effect on the relative abundance of
the dominant 36-carbon PIs was observed after viral infection
of thewild-type cells. Furthermore, the uninfectedTrp53 +/ lslR273H
MEFs, which express only one copy of wild-type Trp53, also
showed no significant change in 36-carbon PI-lipids compared
to either treated or untreated wild-type controls (Figure 5C). Of
note, fragmentation of the 36-carbon PI-lipids that were enriched
subsequent to expression of mutant Trp53 showed that >80% of
this lipid were 18:1/18:1 with <15% of 18:0/18:2 composition
(data not shown). This observation is suggestive of an increase
in production of, or incorporation of, oleic acid (18:1) into PI-
destined molecules as being prominent in the shift we observe.
Shifts to Shorter Acyl Chain Content Subsequent to p53
Mutation Do Not Occur in All Phospholipids
To further shed light on the mechanism of the shift to 36-carbon
PIs seen in malignancies subsequent to p53mutation, we devel-Figure 3. Initiating Genetic Events Contribute to Changes in PI Charac
(A) Comparison of PI characteristics from normal mouse pancreas (mean mea
pancreas-cancer-derived tumor lines of each of two distinct genotypes, initiated w
are displayed; error bars, ±SD).
(B) Assessment of the PI characteristics of Trp53 null MEFs. Mean measuremen
14 Cell Reports 10, 8–19, January 6, 2015 ª2015 The Authorsoped a method for the analysis of phosphatidylcholine (PC) (Fig-
ure S4). Analysis of a panel of cultured cell lines, including those
that harbored almost exclusively 38-carbon PI content (NIH 3T3,
PC3, Capan-2), demonstrated no remarkable difference be-
tween the lines tested in terms of PC-lipid spectra. Unlike Pl
lipids, PC-lipid content in all the cells tested was primarily
composed of 34- and 36-carbon lipids (Figure S5). No apparent
change across cell lines was observed, irrespective of TP53 sta-
tus. These data suggest that the observed alterations in acyl
chain content subsequent to p53mutation are not characteristic
of all phospholipids.
PC and PI share a common precursor: phosphatidic acid (PA).
Synthesis of PI fromPA occurs via two enzymatic steps involving
first cytidine diphosphate diacylglycerol synthase and then cyti-
dine diphosphate diacylglycerol inositol phosphatidyltransferase
(‘‘phosphatidylinositol synthase’’). Generation of PC from PA in-
volves two sequential enzymatic steps requiring phosphatidic
acid phosphatase then cholinephosphotransferase (Holthuis
and Menon, 2014). It is unclear as to how exactly the latter syn-
thesis steps of PC and PI might contribute to different acyl chain
moieties being present in these different lipid types subsequent
to p53 mutation. It might be plausible, however, that incorpora-
tion of different fatty acids into PA leads to accumulation of
distinct pools of this precursor lipid, localized in different mem-
brane regions in the cell. If enzymes required for the synthesis
of PI and PC have differential access to different PA pools, this
may in part explain differences in the fatty acid content seen in
these lipid types in the context of p53 mutation. Alternatively,
PI remodelling does occur such that the composition of mature
PIs can be altered also after their formation (Darnell et al.,
1991). Investigation of the influence of p53 mutation on enzymes
responsible for such remodelling may further define the step at
which acyl chain composition changes in PI molecules occurs.
DISCUSSION
The PIP second messengers consist of lipid tails linked to the
inositol head group, upon which information is presented. In
the case of phosphoinositide biology, research into the func-
tional roles of the lipid tails has lagged behind the study of how
information is encoded. Many biological information systems,
most famously nucleic acids, consist of structural backbones
that carry chemically coded additional information. As was the
case in understanding and correlating DNA backbone methyl-
ation to disease progression (Feinberg and Vogelstein, 1983),
quantitative, reproducible technology is a critical prerequisite
for the deciphering of biological roles that can be attributed to
the PIP scaffolds. It is intriguing that the PIP acyl chains have
the potential for far greater molecular flexibility than the inositol
sugar head group: only seven discrete phosphorylation states
are known for PIPs. In contrast, the variety of lipids that can be
added to two positions on the glycerol linker, consideringteristics in Cancer Progression
surements of technical triplicates are displayed; error bars, ±SEM) and two
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saturation status, double-bond position, as well as carbon con-
tent, is in far excess of the combinatorial possibilities that are
mediated by the currently known PIP modifying kinases and
phosphatases.
Using mass spectrometry, we have defined the spectrum of
phosphoinositide second messenger lipid tails in a rapid, repro-
ducible, and high-throughput manner. Our results show that (1)
cultured cancer cell lines present their own unique PI character-
istic ‘‘fingerprints’’; (2) the PI lipid tails of cells are limited to very
few species by mass, which have a total acyl chain carbon con-
tent of 34, 36, or 38 atoms; (3) noncancerous tissue exhibits
largely 38-carbon species; (4) in contrast, malignant cells contain
the shorter acyl chain lipids totaling 34 and 36 carbons; and (5)
the shift to lower carbon content PI lipid tails can be caused by
p53 mutation.
We observed the shift to low carbon content when comparing
the two pancreatic cancer cell lines MiaPaCa-2 and Capan-2. It
has been reported that the Capan-2 cells, which show dominant
38-carbon content PIs, retain wild-type p53 status (Caldas et al.,
1994; Loukopoulos et al., 2004), a finding that we confirmed in
our analysis. In contrast, the MiaPaCa-2 cells with high 34-
and 36-carbon PI lipid content harbor a point mutation in the
Tp53 gene codon 248 and loss of the remaining wild-type allele.
Note that both cell lines harbor mutant KRAS (Aoki et al., 2000;
Berrozpe et al., 1994; Kita et al., 1999; Loukopoulos et al.,
2004; Moore et al., 2001). Furthermore, sequencing of a panel
of cancer cell lines has provided further evidence that Tp53
mutation is correlated to modulatory effects on cellular PI com-
position. Employing a lox-stop-lox mutant Trp53 MEF system
allowed the unambiguous identification of mutant Trp53 as a
modulator of cellular PI content. Our studies in no way indicate
that p53 is the sole effector molecule responsible for alterations
in PI characteristics, but they are indicative of this gatekeeper
gene regulating lipid-specific pathways. HCT116 cells are Tp53
wild-type (Lee et al., 2004) and yet possess abundant 36-carbon
PIs. Similarly, HeLa cells also possess wild-type p53 genes and a
significant amount of 36-carbon PIs. However, this cervical can-
cer cell line is positive for human papillomavirus 18, which is
known to induce outcomes that are similar to p53mutation itself
(Kessis et al., 1993). Resultantly, it is likely that multiple aberra-
tions, which may be acquired during malignancy, can give rise
to alterations in PI cellular content of which p53 mutation is
one. Although p53 activity has hitherto not been linked to PIP
biology and the associated signaling, mutant p53 protein has
been described to increase the expression of genes encoding
components of themevalonate pathway, thereby altering cellular
cholesterol levels and promoting breast cancer (Santos and
Schulze, 2012). Whether the effects of mutant p53 on PIs
observed in our studies is due to aberrant target gene promoter
binding remains to be shown. Of note, all mutation types
observed in the DNA-binding domain of p53 seem associated
with the lipid-changing activity observed in our study.Figure 4. p53 Mutation Is Associated with Modulation of PI Content
(A) PCR amplification of p53 exons 5–8 in selected human cancer cell lines. Sequ
(B) Sequence traces of selected cancer cell lines showing identifiedmutations and
DNA-binding domain of p53.
16 Cell Reports 10, 8–19, January 6, 2015 ª2015 The AuthorsThe PI analysis methodology we present can be achieved
within minutes, e.g., during an ongoing operation (Balog et al.,
2013), which is in stark contrast to the time frame for gene
sequencing. Thus, it could assist intraoperative pathology calls
with molecular information on tissue to guide surgeons on the
needed extent of resection around a lesion.
It still remains to be determined if and how the different lipid
chain lengths could be causally involved in malignancy. Lipid
‘‘packing defects’’ contribute to the identity of lipid membranes
(Bigay and Antonny, 2012). Thus, the change in PIP lipid tails
could cause differential cellular localization of PIP signaling.
Another intriguing hypothesis could involve the phosphatidylino-
sitol transfer proteins (reviewed in Cockcroft, 2012), which are
among the proteins that can selectively interact with PIPs based
on their lipid composition. Phosphatidylinositol transfer protein a
is an intracellular lipid transporter that transfers both PIP and
phosphatidylcholine and has been shown to preferentially use
PIs with shorter acyl chains (Hunt et al., 2004).
The alterations in PI acyl chain configuration measured in our
studies raises the intriguing question of how these changes
are, if at all, represented in the primary signaling phosphoinosi-
tides; primarily PIP3. Stimulation of cells by different agonists
results in different molecular configurations of PIP3 being
generated, which is highly suggestive of phosphoinositides of
specific acyl configuration being converted to the triple-phos-
phate form by specific head-group-catalyzing enzymes (Wake-
lam, 2014). It has also been hypothesized that alternate acyl
chain compositions on phosphoinositides confer different ori-
entation of the lipid head group relative to the membrane
(Wakelam, 2014). Although singular lipid-binding domains
may not realize altered binding tendencies in different cases
of head-group orientation, the interaction of domains such as
the phosphoinositide 3 phosphate-binding FYVE motif, which
in the case of Hrs, for example, functions in tandem, may expe-
rience differing binding characteristics in such scenarios.
Further understanding of the specific functional relevance of
PI acyl chain configuration and determination of the prevalence
of these molecules being converted into signaling-active PIP3
via subsequent head-group modifications would provide a
fascinating insight into the role of PI tail chemistry in signaling
and disease.
Taken together, our findings identify a rapid and reliable high-
throughput method to test the value of PI lipid tails as biomarkers
for p53 status in tissue. Seeing these effects in pancreatic malig-
nancies, where PI3K/AKT signaling through PIPs is thought to
play a minor role next to K-RAS and p53 alterations, points to
a second, lipid-driven layer of PIP signaling in cancer. Our obser-
vations point to mutation of Tp53 as an important factor in re-
modeling of cellular PIs. Investigation of the exact mechanism
by which this genetic change gives rise to this phenomenon
would provide fascinating insight into the effects of tumor sup-
pressor mutations in lipid composition. If an exact enzyme canencing primers produced a single amplicon used for subsequent sequencing.
corresponding PI characteristics. All identifiedmutations were identified in the
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Figure 5. p53 Mutation Modulates PI Fingerprints
(A) Infection of Trp53 wild-type and Trp53wild-type/lslR270HMEFs with adenovirus encoding Cre recombinase and lipid analysis was performed blinded. In total, 12
cell lines were generated to form genetic biological replicates. Correlation of Trp53 genotype with lipid status demonstrates that levels of 36-carbon PIs (861m/z)
increase subsequent to Trp53 R270H expression.
(B) Analysis of eight biological replicates of Cre-treated Trp53wild-type/lslR270H MEFs demonstrates that all lines exhibit an increase of PI 861 m/z; 861 m/z
abundance in Cre-treated cells is displayed as fold-change relative to the same line prior to Cre addition.
(C) Quantification of PI 861 m/z relative to the most abundant PI species (885 m/z) pre- and post-Cre addition (two-tailed t test; whiskers, ±SD).be identified which is responsible for mediating such changes,
inhibition of this protein and observation of the cellular response
in terms of malignant transformation may provide a hitherto-un-
considered approach for treating Tp53 mutant malignancies.Furthermore, elucidation of the exact influence that regulation
of PI backbones has on PI3K/AKT-mediated signaling will create
a new understanding of how p53 mutation modulates this can-
cer-related signaling axis.Cell Reports 10, 8–19, January 6, 2015 ª2015 The Authors 17
EXPERIMENTAL PROCEDURES
Generation of Murine Pancreatic Tumor-Derived Cell Lines
Cell lines were derived from animals transgenic for Pdx1-Cre, carrying the
Kras lsl-G12D/ + alleles. Double-mutant mice also harbored the Trp53 lsl-R172H/ +
alleles (Tuveson and Hingorani, 2005). All protocols for mouse experiments
were in accordance with institutional guidelines and were approved by the
IACUC.
Lipid Analysis
Lipid extraction from tissue culture material has been described previously
(Milne et al., 2005). Extracted lipids were analyzed by a Vantage triple-stage
quadrupole mass spectrometer (Thermo Scientific) in negative ion mode
with the heated electrospray ionization (HESI-II) ion source.
PCR Amplification and Sequencing of p53 Exons 5–8
PCR reactions, primer sequences, and amplification conditions and Sanger
dideoxysequencing methodology have been described previously (Park
et al., 2010).
Extensive descriptions of methodology are included in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.12.010.
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